Preliminary results from the ASPIRE trial have been promising, showing improved survival rates in certain cancer types, particularly when targeted therapies are combined with immunotherapy. For instance, in non-small cell lung cancer, the combination of a PD-1 inhibitor with a tyrosine kinase inhibitor has led to significant improvements in both overall and progression-free survival. However, results vary depending on the cancer type and the specific treatment regimen.